Ramelteon(melatonin receptor agonist)for neuromuscular degenerative disease and neuroimmunological disease;examination for safety

Ramelteon(melatonin receptor agonist)for neuromuscular degenerative disease and neuroimmunological disease;examination for safety - Ramelteon(melatonin receptor agonist)for neurological disease;examination for safety

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006298

Enrollment

Registered

2011-09-09

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromuscular degenerative disease and neuroimmunological disease

Interventions

SPO2 monitoring overnight without Ramelteon. SPO2 monitoring overnight with Ramelteon.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed as neuromuscular disease and neuroimmunological disease. Patients who obtained mutual agreement of participation and agreed for outline of intervention trial.

Exclusion criteria

Exclusion criteria: As a rule ,these patients are excluded; patients whose %VC are 50% or less,patients who has respiratory disease.

Design outcomes

Primary

Measure	Time frame
No significant difference on ODI3 before and after Ramelteon administration.	—

Secondary

Measure	Time frame
Ramelteon utility should be proven by sleep score.	—

Countries

Japan

Contacts

Public Contactchiharu kugimoto

Yokohama city University Department of neurology

045-78-2725

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026